A	
20	
Ca	
$\leq$	

## Notice of Allowability

Application No.	Applicant(s)
10/043,366	KATSUYAMA, IWAO
Examiner	Art Unit
Daniel M Sullivan	1636

	Daniel M Sullivan	1636	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIG	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to and MPEP 1308.	olication. If not include will be mailed in due withdrawal from issu	ed course, <b>THIS</b>
1. This communication is responsive to the interview of 11 Fe	bruary 2004 (see attached interview	summary).	
2. The allowed claim(s) is/are <u>44-47,49-56,58,59,61-69 and 7</u>	<u>1-75</u> .		
3. The drawings filed on 03 January 2003 are accepted by the	e Examiner.		
<ul> <li>4.  Acknowledgment is made of a claim for foreign priority un a)  All b)  Some* c)  None of the: <ol> <li>Certified copies of the priority documents have</li> <li>Certified copies of the priority documents have</li> <li>Copies of the certified copies of the priority documents have</li> </ol> </li> <li>Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).</li> </ul> <li>* Certified copies not received:</li>	been received. been received in Application No		tion from the
Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONMI THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. A SUBSTITUTE OATH OR DECLARATION must be submit	ENT of this application.  tted. Note the attached EXAMINER'	S AMENDMENT or N	
INFORMAL PATENT APPLICATION (PTO-152) which give	s reason(s) why the oath or declarat	tion is deficient.	
<ul> <li>6. CORRECTED DRAWINGS ( as "replacement sheets") must (a) including changes required by the Notice of Draftsperson 1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1.4)</li> </ul>	on's Patent Drawing Review (PTO-9	ffice action of	hoole) of
each sheet. Replacement sheet(s) should be labeled as such in th	e header according to 37 CFR 1.121(d	I).	
7. DEPOSIT OF and/or INFORMATION about the depos attached Examiner's comment regarding REQUIREMENT F	iit of BIOLOGICAL MATERIAL m FOR THE DEPOSIT OF BIOLOGICA	nust be submitted. N AL MATERIAL.	lote the
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal Pa 6. ☑ Interview Summary ( Paper No./Mail Date 3), 7. ☑ Examiner's Amendm 8. ☐ Examiner's Statemen 9. ☐ Other	(PTO-413), e <u>attached</u> . ent/Comment	

Art Unit: 1636

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kristi Rupert on 11 February 2004.

The application has been amended as follows:

## In the claims

Claims 64 and 66 have been amended as follows:

- 64. A method of screening or evaluating a medicine <u>for</u> treatment or improvement of a corneal epithelial damage, which comprises the steps of:
- (i) administering a medicine to a damaged ocular cornea of the experimental animal claimed in Claim 44; and
  - (ii) evaluating a therapeutic effect thereof on the corneal epithelial damage.
- 66. A method of screening or <u>evaluating a medicine</u> for treatment or improvement of a corneal <u>evaluating</u> epithelial damage, which comprises the steps of:
- (i) administering a medicine to a damaged ocular cornea of the experimental animal claimed in Claim 55; and
  - (ii) evaluating a therapeutic effect thereof on the corneal epithelial damage.

Application/Control Number: 10/043,366

Art Unit: 1636

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel M Sullivan whose telephone number is 571-272-0779. The examiner can normally be reached on Monday through Friday 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DMS

PRIMARY EXAMINER